Navigation Links
Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
Date:6/26/2009

rporate Web site, www.takeda.com.

About Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit www.tpna.com.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 Frost & Sullivan,s ... looks forward to speaking at the 2010 ... place on January 9, 2010 in Las ... emerging market of consumer-based digital health and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Bujnoch focuses ...
(Date:12/16/2009)... 16 Naurex Inc., a new clinical ... other CNS disorders based on its novel GFPA ... at a major medical meeting showed that its ... activity with no signs of the CNS-related side ... receptor(1). The studies also showed that GLYX-13,s ...
(Date:12/16/2009)... Savara, Inc., an inhalation drug delivery company, ... in its Series A financing round, exceeding the targeted ... Funds raised in the Series A round will be ... ,, "We now have the runway and resources ... NanoCluster technology," said Rob Neville, CEO of Savara. ...
Breaking Medicine Technology:Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2Pitt researchers find promising candidate protein for cancer prevention vaccines 9472 1Pitt researchers find promising candidate protein for cancer prevention vaccines 9472 2Nanotechnology Transforms Pain Relief 53652 1Nanotechnology Transforms Pain Relief 53652 2Nanotechnology Transforms Pain Relief 53652 3Nanotechnology Transforms Pain Relief 53652 4Aetna 28 Percent Profit Drop Signals Storm Clouds for Healthcare 53650 1Aetna 28 Percent Profit Drop Signals Storm Clouds for Healthcare 53650 2
... MOUNTAIN VIEW, Calif., Feb. 23 MAP,Pharmaceuticals, Inc. ... of its initial,Phase 3 clinical trial of Unit ... with asthma. The Company announced that the ... control as assessed by,changes from baseline in nighttime ...
... 23 People who start smoking before age ... according to a study released today that will be presented ... Seattle, April 25 to May 2, 2009. The study involved ... people in a larger study. The people with MS were ...
Other Medicine Technology:MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3Young Smokers Increase Risk for Multiple Sclerosis 2
(Date:12/16/2009)... promote Massachusetts companies through annual marketing campaign , ... ... BioSpace unveiled the 2010 Genetown™ Hotbed Campaign as ... , ,Genetown is sponsored by MassBio and showcases ... The campaign places each entity’s brand on an electronic ...
(Date:12/16/2009)... shows, , , WEDNESDAY, Dec. 16 (HealthDay News) -- Average ... 78 years, a record high, federal health officials said ... to live to 80.4 years on average and men ... U.S. Centers for Disease Control and Prevention. , ... than their parents, life expectancy in the United States ...
(Date:12/16/2009)... 16 Medical travel facilitator Companion Global ... Puerto Rico into its network of international hospitals ... than those at mainland U.S. facilities. ,, The ... travel assistance and preferred pricing for its individual ... at either HIMA San Pablo Bayamon or HIMA ...
(Date:12/16/2009)... -- MassMutual,s Retirement Services Division has announced plans ... in Q2 2010. The new platform will include ... change materials in a variety of themes. Plan ... a menu of creative options to support the ... The new RetireSmart participant engagement platform will be ...
(Date:12/16/2009)... The DNA of a 1st century shrouded man found in ... Jerusalem has revealed the earliest proven case of leprosy. Details ... PloS ONE Journal. , The molecular investigation was ... of the Sanford F. Kuvin Center for the Study of ... Prof. Carney Matheson and Ms. Kim Vernon of Lakehead University, ...
Breaking Medicine News(10 mins):Health News:Thriving Bioscience Region Leaves Its Mark 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 2Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 3
... AGGRESSIVE VACCINATION SCHEDULE TO,COMBAT RISING AUTISM RATES?, ... who,regressed into autism after receiving vaccines are expressing ... be catching on to the,link between vaccines and ... by investigative journalist,David Kirby reported details of a ...
... heart disease in these mothers, , , FRIDAY, March 28 ... a woman,s risk of having high cholesterol later, a ... of heart disease even further down the line for ... presented Thursday at the Society for Gynecologic Investigation annual ...
... League of,Democratic Women will conduct a mock debate and ... Barack Obama., "We,re not expecting the candidates themselves ... will be represented by two local,volunteers supporting the candidate,s ... at 6 p.m. Tuesday at the Raleigh County,Public Library. ...
... at UC San Diego Medical Center removed an ... in the United States. Following the 50-minute procedure, ... Removal of diseased organs through the bodys natural ... and no scarring. Key to these surgical clinical ...
... innovative programs, partnerships, and ... mentoring in the workplace, WOONSOCKET, R.I., March 28 ... programs to recruit and retain,employees, was joined by other ... in Washington, D.C. for a discussion on the,multigenerational workforce ...
... SYK ) announced today that it will provide webcast ... be held:, April 23, 2008 - 2:00 ... Michigan Information about the webcast, which will include ... is available in the Calendar of,Events area of the ...
Other Medicine News:Health News:MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at Risk 2Health News:Premature Delivery Linked to High Cholesterol in Moms Later 2Health News:Premature Delivery Linked to High Cholesterol in Moms Later 3Health News:Appendix 2Health News:CVS Caremark Presents at NCOA-ASA Conference on Company's Commitment to Recruiting and Retaining Mature Workers 2Health News:CVS Caremark Presents at NCOA-ASA Conference on Company's Commitment to Recruiting and Retaining Mature Workers 3Health News:Stryker to Provide Webcast and Telephone Access to Annual Shareholder Meeting 2
Produces vacuum pressures required for 96 well kits...
... pump is perfect for electrophoresis gel drying, ... vacuum of greater than 29 inches of ... well with the Model 583 gel dryer. ... 1/4 and 3/8 inch ID vacuum tubing, ...
Produces vacuum pressures required for 96 well kits...
For vacuum-driven processing of spin columns; Reduced sample handling and accelerated processing; Parallel sample processing using QIAGEN spin columns; Easy cleaning of internal components by simpl...
Medicine Products: